Overview

Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors

Status:
Completed

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

An open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 as single-agent therapy and as combination therapy with temozolomide in patients with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Cephalon

Treatments:

Dacarbazine
Temozolomide